Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions
Figure 3
Dabrafenib shows functional selectivity for BRAFV600D/E/K tumor cell growth inhibition.
The functional selectivity of dabrafenib was evaluated by measuring the growth of a range of human tumor cell lines of different genetic mutation status. Cells were treated with a concentration range of dabrafenib in a 3-day proliferation assay and growth IC50 (gIC50) values were measured.